IBT Stock Overview
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IBEX Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.96 |
| 52 Week High | CA$0.97 |
| 52 Week Low | CA$0.52 |
| Beta | -0.045 |
| 1 Month Change | 1.59% |
| 3 Month Change | 30.61% |
| 1 Year Change | 86.41% |
| 3 Year Change | 306.78% |
| 5 Year Change | 823.08% |
| Change since IPO | -31.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| IBT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.5% | -4.3% | -2.5% |
| 1Y | 86.4% | -19.4% | -0.4% |
Return vs Industry: IBT exceeded the German Biotechs industry which returned -13.9% over the past year.
Return vs Market: IBT exceeded the German Market which returned 4.1% over the past year.
Price Volatility
| IBT volatility | |
|---|---|
| IBT Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: IBT's share price has been volatile over the past 3 months.
Volatility Over Time: IBT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | n/a | Paul Baehr | www.ibex.ca |
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research.
IBEX Technologies Inc. Fundamentals Summary
| IBT fundamental statistics | |
|---|---|
| Market cap | €23.95m |
| Earnings (TTM) | €2.70m |
| Revenue (TTM) | €5.43m |
8.9x
P/E Ratio4.4x
P/S RatioIs IBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBT income statement (TTM) | |
|---|---|
| Revenue | CA$8.00m |
| Cost of Revenue | CA$2.23m |
| Gross Profit | CA$5.77m |
| Other Expenses | CA$1.79m |
| Earnings | CA$3.98m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.16 |
| Gross Margin | 72.11% |
| Net Profit Margin | 49.70% |
| Debt/Equity Ratio | 0% |
How did IBT perform over the long term?
See historical performance and comparison